Cancer therapy: targeting cell cycle regulators

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cyclins and cyclin-dependent kinases (CDKs) regulate DNA synthesis and cell division.
• Dysregulation of cell cycle control is a hallmark of cancer, often involving elevated cyclins and CDKs.
• Understanding cell cycle response to chemotherapy is crucial for enhancing treatment efficacy and overcoming resistance.

Purpose of the Study:

• To review the development of novel therapeutic agents targeting cell cycle pathways in human cancers.
• To discuss drugs that directly inhibit tumor cell mitosis.
• To highlight the potential of small molecule CDK inhibitors derived from natural products.

Main Methods:

• Literature review of recent advancements in cell cycle-targeted cancer therapeutics.
• Analysis of drug mechanisms interfering with mitotic processes.
• Exploration of natural product-derived compounds as CDK inhibitors.

Main Results:

• Elevated cyclins and CDKs are common in various human cancers.
• Novel agents are being developed to target specific cell cycle pathways.
• Natural products show promise as sources for small molecule CDK inhibitors.

Conclusions:

• Targeting cell cycle pathways presents a promising strategy for cancer therapy.
• Developing drugs that inhibit mitosis and utilize natural product-derived CDK inhibitors can improve treatment outcomes.
• Further research is needed to overcome drug-induced cytotoxicity and resistance.